DR. MICHAEL S. RAFII, M.D., PH.D.
Neurology at Gilman Dr, La Jolla, CA

License number
California A94804
Category
Neurology
Type
Neurology
Address
Address
9500 Gilman Dr #0949, La Jolla, CA 92093
Phone
(858) 622-5800

Professional information

Michael S Rafii Photo 1

Michael S Rafii, La Jolla CA

Specialties:
Neurologist
Address:
9500 Gilman Dr, La Jolla, CA 92093
Uc San Diego, La Jolla, CA 92093
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)


Michael S Rafii Photo 2

Dr. Michael S Rafii, La Jolla CA - MD (Doctor of Medicine)

Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
UCSD Shiley Marcos Alzheimer
8950 Villa La Jolla Dr STE 129, La Jolla 92037
(858) 622-5800 (Phone)
UCSD Neurology Clinic
9350 Campus Point Dr STE B, La Jolla 92037
(858) 657-8540 (Phone)
Certifications:
Neurology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Brown Medical School
Graduated: 2002


Michael S Rafii Photo 3

Michael S Rafii, San Diego CA

Specialties:
Neurology
Work:
Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161 Perlman Medical Offices
9350 Campus Point Dr, La Jolla, CA 92037
Education:
Brown University (2002)


Michael Rafii Photo 4

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
8138154, Mar 20, 2012
Filed:
Jul 6, 2009
Appl. No.:
12/498172
Inventors:
Justin R. Fallon - Providence RI, US
Beth McKechnie - Franklin MA, US
Michael Rafii - La Jolla CA, US
Hilliary Creely - Providence RI, US
Mark A. Bowe - Damascus MD, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
Assignee:
Brown University Research Foundation - Providence RI
International Classification:
A61K 38/00, A61K 45/00, A61K 39/00, A01N 37/18
US Classification:
514 177, 514 76, 514 83, 514 165, 514 179, 4242791, 4241841, 4241851, 4241921
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.